Compare Logitech International SA (LOGI) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Logitech International SA vs Travere Therapeutics Inc. Common Stock — how do they compare? Logitech International SA trades at $100.88 (market cap $14.62B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Logitech International SA is far larger — about 2.9× Travere Therapeutics Inc. Common Stock's market cap, and Logitech International SA pays a 1.64% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Logitech International SA for 92 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| LOGI | TVTX | |
|---|---|---|
Market Cap | $14.62B | $5.02B |
Volume | 345,412 | 2,060,842 |
Sector | Technology | Health |
52-Week High | $126.69 | $67.52 |
52-Week Low | $85.84 | $26.79 |
Typical Hold Time | 92 Days | 0 Days |
Enterprise Value | $12.95B | $5.15B |
Dividend Yield | 1.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Logitech (LOGI) trades at $102.77, up 4.52% on the day, reflecting strong momentum. The stock exhibits a bullish technical trend, supported by moving averages, and trades near its pivot point of $102. Recent earnings have consistently beaten estimates, with Q2 2026 EPS of $1.85 surpassing the $1.26 expectation. The company maintains robust profitability, with a net income margin of 16.28% and ROE of 35.29%. Positive developments include new product launches like the Zone Vibe Pro headset and a partnership with SEGA for Crazy Taxi: World Tour.
The outlook for LOGI is cautiously optimistic, driven by earnings beats and strategic initiatives, though analyst consensus is mixed with a $107 price target. Key opportunities include product innovation and hybrid work trends, while risks involve chip shortage challenges and competitive pressures. The stock's valuation, with a P/E of 18.55, appears reasonable given growth prospects, but investors should monitor execution against guidance.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
